These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39366184)

  • 1. Recent progress in cancer vaccines and nanovaccines.
    Poudel K; Vithiananthan T; Kim JO; Tsao H
    Biomaterials; 2025 Mar; 314():122856. PubMed ID: 39366184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Nanovaccines: Nanomaterials and Clinical Perspectives.
    Desai N; Chavda V; Singh TRR; Thorat ND; Vora LK
    Small; 2024 Aug; 20(35):e2401631. PubMed ID: 38693099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanovaccines: An effective therapeutic approach for cancer therapy.
    Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
    Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy.
    Wells K; Liu T; Zhu L; Yang L
    Nanoscale; 2024 Oct; 16(38):17699-17722. PubMed ID: 39257225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy.
    Jahanafrooz Z; Oroojalian F; Mokhtarzadeh A; Rahdar A; Díez-Pascual AM
    Drug Dev Res; 2024 Aug; 85(5):e22244. PubMed ID: 39138855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanovaccines with cell-derived components for cancer immunotherapy.
    Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
    Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
    Wang QT; Liu YX; Wang J; Wang H
    ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
    Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y
    Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment.
    Zhao G; Wang S; Nie G; Li N
    Med; 2024 Jul; 5(7):660-688. PubMed ID: 38582088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node-targeting nanovaccines for cancer immunotherapy.
    Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
    J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
    Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
    ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
    Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
    Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance.
    Pan W; Wang Y; Chen G; Ma X; Min Y
    Biomaterials; 2025 Feb; 313():122788. PubMed ID: 39236628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting.
    Achmad H; Saleh Ibrahim Y; Mohammed Al-Taee M; Gabr GA; Waheed Riaz M; Hamoud Alshahrani S; Alexis Ramírez-Coronel A; Turki Jalil A; Setia Budi H; Sawitri W; Elena Stanislavovna M; Gupta J
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109434. PubMed ID: 36402068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Minimalist Pathogen-Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy.
    Miao Y; Niu L; Lv X; Zhang Q; Xiao Z; Ji Z; Chen L; Liu Y; Liu N; Zhu J; Yang Y; Chen Q
    Adv Mater; 2024 Nov; 36(44):e2410715. PubMed ID: 39210649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.